ADMA Biologics Inc Company Profile
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ADMA Biologics at a glance
ADMA Biologics Inc (NASDAQ: ADMA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Ramsey, NJ. ADMA Biologics is led by Mr. Adam S. Grossman and employs about 640 people. At a market capitalization of $2.28 billion, it is considered a mid-cap company.
Its SEC Central Index Key (CIK) is 0001368514, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does ADMA Biologics do?
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- ADMA Biologics Inc
- Ticker
- NASDAQ: ADMA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Adam S. Grossman
- Employees
- 640
- Headquarters
- 465 State Route 17, Ramsey, NJ, United States
- Phone
- 201 478 5552
- Website
- admabiologics.com
- Market cap
- $2.28B
- SEC CIK
- 0001368514
Companies similar to ADMA Biologics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RXRXRecursion Pharmaceuticals Inc. Class A | 4.27 | -7.78% | $2.29B | vs ADMA |
| BCRXBioCryst Pharmaceuticals Inc. | 8.40 | +5.66% | $2.15B | vs ADMA |
| ALVOAlvotech | 5.85 | -4.72% | $2.09B | vs ADMA |
| VCELVericel Corporation | 40.74 | +1.72% | $2.09B | vs ADMA |
| BEAMBeam Therapeutics Inc. | 24.77 | -1.82% | $2.56B | vs ADMA |
| VIRVir Biotechnology Inc. | 11.52 | -0.69% | $1.95B | vs ADMA |
| NVAXNovavax Inc. | 11.22 | -0.88% | $1.85B | vs ADMA |
| MESOMesoblast Limited ADR | 13.94 | +2.42% | $1.81B | vs ADMA |